May 2, 2022

TFF Pharmaceuticals Announces Multiple Presentations Highlighting Broad Applicability of its Thin Film Freezing Technology at Respiratory Drug Delivery Meeting (RDD)

April 29, 2022

TFF Pharmaceuticals to Hold First Quarter 2022 Financial and Business Results Conference Call on May 11, 2022

April 19, 2022

TFF Pharmaceuticals Announces Safety and Pharmacokinetic Data from Phase 1 Study of Niclosamide Inhalation Powder

March 24, 2022

TFF Pharmaceuticals Reports Fourth Quarter and Full Year 2021 Financial Results and Provides Business Update

March 17, 2022

TFF Pharmaceuticals Enters into CRADA with the U.S. Army and The Geneva Foundation to Develop Dry Powder Needle-free Medical Countermeasures

March 11, 2022

TFF Pharmaceuticals to Participate at the 34th Annual Roth Conference

March 9, 2022

TFF Pharmaceuticals to Hold Fourth Quarter and Full Year 2021 Financial and Business Results Conference Call on March 24, 2022

March 1, 2022

TFF Pharmaceuticals and Catalent Announce New Inhalation Dry Powder Development and Manufacturing Agreement

February 24, 2022

TFF Pharmaceuticals Announces Inhaled Niclosamide Significantly Inhibits Viral Replication of the Omicron Variant of SARS-CoV-2

January 27, 2022

TFF Pharmaceuticals Completes Enrollment in Phase 1 Study Evaluating Inhaled Formulation of Niclosamide to Treat COVID-19